To determine whether LTD4-BPT could be an effective indicator for predicting efficacy of anti-leukotriene therapy, allowing objective proofs for the use of LTRA among asthmatics in a specific sensitive to leukotriene population of asthma. Hypothesis ：Monteluakst can better improve pre-challenge FEV1 from baseline in leukotriene-sensitive group than leukotriene-insensitive group.
Study Type
OBSERVATIONAL
Enrollment
60
Guangzhou Institute of Respiratory Disease, State Key Laboratory of Respiratory Disease
Guangzhou, Guangdong, China
RECRUITINGwhether there was improvement in pre-challenge FEV1%
The primary outcome was a qualitative measure, with the results being expressed as either yes or no ('1' or '0' in Logistic model).A higher FEV1% is more suggestive of instability of asthma control.
Time frame: from commencement of LTRA therapy to (7±2) days and (56±5) days
whether there was improvement in post- treatment FENO
In Logistic regression model, whether there was improvement shown in post-treatment FENO as compared with pre-treatment level was expressed as either 'yes' or 'no', with symbols of '1' or '0'. Thus the measure was qualitative one. FENO represented fractional exhaled nitric oxide above.
Time frame: from commencement of LTRA therapy to (7±2) days and (56±5) days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.